:
Glioblastoma multiforme (GBM) is the typical categories of the most common and aggressive brain tumors with
high incidence more often in older adults. The etiology of GBM has not been fully elucidated. Clinically, GBM is
characterized by highly proliferative activity in the glial cells, and its complete resection is impossible, and radiotherapy is
not always efficient. GBM remain a therapeutic challenge in neuro-oncology because there is no treatment that achieves a
significant improvement in survival. In this regard, the identification of newer drug therapy for the treatment of GBM is
gaining popularity. However, the process of identifying new targets and development of new leads for screening suitable
drug candidates require the investment of resources like time, money, and efforts. Thus, the use of PUFAs therapeutic
moieties for such tumor treatment has yielded significant interest owing to their cost-effective availability, limited sideeffects, and insensitivity towards drug resistance. Nevertheless, implications of the nanostructured therapeutic systems in
delivering the PUFAs can provide significant augmentation in their biopharmaceutical performance and antitumor activity
over the existing synthetic drug therapy. Now a days various studies showed that polyunsaturated fatty acids especially glinolenic acid (GLA) have selective tumoricidal action especially against malignant gliomacells.The present, in this regard,
endeavors to provide an insight into the applications of nanomedicines-loaded with PUFAs therapeutics for effective
treatment of GBM and associated diseases.
Nanostructured Therapeutic Systems of PUFA’S for the Treatment of Glioblastoma Multiforme
